Relatlimab is under clinical development by Bristol-Myers Squibb and currently in the Phase I, Phase II and Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Relatlimab’s likelihood of approval (LoA) and phase transition for Cervical Cancer took place on 14 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 14 Dec 2022 increased Relatlimab’s Phase Transition Success Rate (PTSR) for Gastric Cancer, and increased LoA and PTSR for Head And Neck Cancer Squamous Cell Carcinoma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Relatlimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Relatlimab (BMS-986016) is under development for the treatment of hematological malignancies, renal medullary carcinoma (RMC), newly diagnosed older acute myeloid leukemia, metastatic hepatocellular carcinoma (HCC), advanced unresectable or metastatic basal cell carcinoma, relapsed and refractory acute myeloid leukemia, non-Hodgkin lymphoma, relapsed refractory multiple myeloma, Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia (CLL), melanoma, multiple myeloma, gastric cancer, soft tissue sarcoma recurrent head and neck squamous cell carcinoma, non-small cell lung cancer, cervical cancer, ovarian cancer, bladder cancer, renal cell carcinoma, hepatocellular cancer, recurrent glioblastoma multiforme, gliosarcoma, colorectal cancer (solid tumors) and metastatic or unresectable melanoma (first line therapy). It is administered intravenously. It is a monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities.
It was under development for solid tumors in Japan.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
Quick View Relatlimab LOA Data
|Highest Development Stage|